POLB 001 poster to be presented at EHA 2026

Poolbeg Pharma PLC

13 May 2026

 

Poolbeg Pharma plc

POLB 001 poster to be presented at EHA 2026 Congress

13 May 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it will present data on POLB 001 at the European Hematology Association Congress ("EHA"), taking place 11-14 June 2026 in Stockholm, Sweden.

The abstract, which is available online, outlines further evidence of POLB 001's potential to prevent cancer immunotherapy-induced Cytokine Release Syndrome ("CRS"). The data presented at EHA will include in vivo models showing the capacity of POLB 001 to reduce multiple key CRS-related cytokines (including TNF, IFNγ, and IL-6) and in vitro data showing that POLB 001 can inhibit cytokine production without impairing bispecific antibody-induced tumour cell killing.

EHA is one of the world's leading scientific meetings focused on haematology, bringing together clinicians, researchers, pharmaceutical companies and healthcare professionals to present and discuss the latest advances in blood disorders and related treatments. The congress serves as a major international platform for the presentation of important data, translational research and emerging therapeutic developments across areas including myeloma, leukemia, lymphoma,  and other hematological diseases.

Title: POLB 001, an oral P38 MAPK Inhibitor for the Prevention of Cytokine Release Syndrome

Poster Session: Poster Session 2

Session Date and Time: Saturday, 13 June 2026, 18:45 - 19:45 CEST

Location: Stockholmsmässan exhibition centre, Stockholm, Sweden

Authors:  Liam Tremble, Paula Maguire, Meena Arora, Joe Froggatt, Jeremy Skillington, Brendan Buckley, Rakesh

Popat, Emma Searle.

Abstract Code: PS1845

To schedule a meeting with the Company, please contact [e-mail].

Liam Tremble, Principal Scientist of Poolbeg Pharma, said: "We look forward to sharing this important data at the European Hematology Association Congress, one of the world's leading forums for advancing haematology research. The findings highlight the potential of POLB 001 to reduce key drivers of CRS while preserving anti-tumour activity. We believe POLB 001 could transform the cancer immunotherapy field through the prevention of CRS, improving patient quality of life and expanding the number of patients that can receive these life-saving cancer immunotherapies."

Enquiries   

Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO	[phone] [e-mail]
Cavendish Capital Markets Ltd (NOMAD & Joint Broker) Geoff Nash, Trisyia Jamaludin (Corporate Finance) Nigel Birks (Life Science Specialist Sales) Harriet Ward (ECM)	[phone]
Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry Davies-Ball (Corporate Advisory) Malachy McEntyre (Corporate Broking)	[phone]
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist	[phone]
Optimum Strategic Communications Nick Bastin, Katie Flint, Elena Bates	[phone] [e-mail]

About Poolbeg Pharma plc

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs. 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

 

END